Unichem Laboratories Past Earnings Performance
Past criteria checks 0/6
Unichem Laboratories's earnings have been declining at an average annual rate of -30.7%, while the Pharmaceuticals industry saw earnings growing at 13.3% annually. Revenues have been growing at an average rate of 7.6% per year.
Key information
-30.7%
Earnings growth rate
-30.7%
EPS growth rate
| Pharmaceuticals Industry Growth | 17.5% |
| Revenue growth rate | 7.6% |
| Return on equity | -0.2% |
| Net Margin | -0.3% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Unichem Laboratories makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 17,747 | -56 | 4,117 | 0 |
| 30 Jun 24 | 17,281 | -606 | 4,096 | 0 |
| 31 Mar 24 | 17,049 | -705 | 4,100 | 0 |
| 31 Dec 23 | 16,753 | 146 | 3,950 | 0 |
| 30 Sep 23 | 15,434 | -1,333 | 3,874 | 0 |
| 30 Jun 23 | 14,566 | -1,795 | 3,675 | 0 |
| 31 Mar 23 | 13,430 | -2,022 | 3,690 | 0 |
| 31 Dec 22 | 13,109 | -865 | 3,696 | 0 |
| 30 Sep 22 | 13,197 | -367 | 3,614 | 0 |
| 30 Jun 22 | 12,815 | 212 | 3,530 | 0 |
| 31 Mar 22 | 12,698 | 331 | 3,468 | 0 |
| 31 Dec 21 | 11,740 | -388 | 3,253 | 0 |
| 30 Sep 21 | 11,890 | -12 | 3,211 | 0 |
| 30 Jun 21 | 12,158 | 204 | 3,152 | 0 |
| 31 Mar 21 | 12,351 | 343 | 3,113 | 0 |
| 31 Dec 20 | 13,581 | 175 | 3,112 | 0 |
| 30 Sep 20 | 13,067 | -206 | 2,989 | 0 |
| 30 Jun 20 | 12,547 | -516 | 2,916 | 0 |
| 31 Mar 20 | 11,037 | -602 | 2,786 | 0 |
| 31 Dec 19 | 12,653 | -113 | 2,745 | 0 |
| 30 Sep 19 | 12,711 | 51 | 2,697 | 0 |
| 30 Jun 19 | 12,366 | -113 | 2,567 | 0 |
| 31 Mar 19 | 11,800 | -256 | 2,475 | 0 |
| 31 Dec 18 | 10,425 | -591 | 2,319 | 0 |
| 31 Mar 18 | 8,146 | -1,331 | 2,090 | 0 |
| 31 Dec 17 | 15,855 | 405 | 4,258 | 585 |
| 31 Mar 17 | 6,977 | -707 | 1,806 | 0 |
| 31 Mar 16 | 13,327 | 1,081 | 3,311 | 416 |
| 31 Mar 15 | 12,018 | 754 | 3,004 | 446 |
| 31 Mar 14 | 11,334 | 1,282 | 4,380 | 505 |
Quality Earnings: 506690 is currently unprofitable.
Growing Profit Margin: 506690 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 506690 is unprofitable, and losses have increased over the past 5 years at a rate of 30.7% per year.
Accelerating Growth: Unable to compare 506690's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 506690 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (20.5%).
Return on Equity
High ROE: 506690 has a negative Return on Equity (-0.23%), as it is currently unprofitable.